Ignite Creation Date:
2024-05-06 @ 3:09 AM
Last Modification Date:
2024-10-26 @ 11:29 AM
Study NCT ID:
NCT02216890
Status:
COMPLETED
Last Update Posted:
2018-04-19
First Post:
2014-08-12
Brief Title:
Safety Study of SGN-CD70A in Cancer Patients
Sponsor:
Seagen Inc
Organization:
Seagen Inc
Study Overview
Official Title:
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status:
COMPLETED
Status Verified Date:
2018-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will examine the safety profile of SGN-CD70A The study will test increasing doses of SGN-CD70A given every 3 weeks or an alternate dosing schedule up to every 6 weeks to small groups of patients The goal is to find the highest dose of SGN-CD70A that can be given to patients without causing unacceptable side effects The pharmacokinetics and antitumor activity of SGN-CD70A will also be evaluated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None